Blood Clotting Products Stability in Ambulances
Part of Blood & lymphatic, Injuries & trauma clinical trials.
This study checks whether two blood clotting medicines (Fibryga and Octaplas LG AB) stay safe and effective when stored in ambulances during real emergencies. The research helps ensure these life-saving products work properly when paramedics need them most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Blood clotting product samples (Fibryga or Octaplas LG AB) must be stored in a ground-based ambulance
- Samples must be available for lab testing at scheduled checkpoints during the study
- Samples must experience normal ambulance storage conditions—no extreme heat, cold, or other unusual treatment
- Packaging must be intact with no damage or leaks
- Complete records of how and when samples were stored must be available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if a fast bedside test for fibrinogen (a protein that helps blood clot) can help guide treatment for trauma patients who are actively bleeding. It may lead to better care in the emergency department.
This trial compares two types of blood tests (a new quick test vs. standard tests) to see which helps doctors better manage bleeding after a severe injury. It is for adults with serious trauma who may have a blood clotting problem.
This trial tests a standard set of emergency blood transfusions for people with life-threatening bleeding from a serious injury. It aims to improve survival by giving blood products quickly before reaching the hospital.
This trial studies how well the body's natural clot-busting system works in people with serious infections or major injuries. It may help doctors find better ways to treat these conditions.
This trial tests a treatment called INTERCEPT Fibrinogen Complex (IFC) to help control bleeding in trauma patients. It is given to patients who arrive at the hospital quickly after injury and have low fibrinogen levels.
This Phase 3 study tests whether giving fibrinogen early can improve outcomes for adults with serious trauma who are actively bleeding. The goal is to help blood clotting work better sooner and potentially reduce complications from uncontrolled bleeding.
Hear when a new Exanguination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.